09:10 Thu 26 Oct 2017
Angle PLC - Total Voting Rights
For immediate release |
|
Total Voting Rights
The figure of 82,297,344 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the
Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement entitled "Proposed Further Subscription For
For further information ANGLE:
|
+44 (0) 1483 343434 |
|
|
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Corporate Broking -
|
+44 (0) 207 220 0500 |
|
+44 (0) 203 705 9330
|
FTI Consulting |
+44 (0) 203 727 1000 +1 212 850 5612 |
Notes for editors
About
ANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.
ANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient blood with ANGLE's ParsortixTM system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The ParsortixTM system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.
As well as cancer, the ParsortixTM technology has the potential for deployment with several other important cell types in the future.
ANGLE stock trades on the AIM market of the
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE